| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4029712 | Ophthalmology | 2007 | 4 Pages |
Abstract
In the rabbit, the vitreous half-life of 0.5-mg intravitreal ranibizumab is 2.88 days, shorter than the half-life of 1.25-mg intravitreal bevacizumab of 4.32 days. No ranibizumab was detected in the serum or the fellow uninjected eye; whereas small amounts of intravitreal bevacizumab have been detected in the serum and fellow uninjected eye.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sophie J. MD, Melissa R. PhD, Joel M. PhD, Jose S. MD, Mohamed K. BS, Ravinder J. PhD,